Staar Surgical Co

STAA

Equity

ISIN null / Valor 972813

NASDAQ (2026-05-05)

USD 27.45+0.59%

Staar Surgical Co
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

STAAR Surgical Company is a U.S.-based medical device firm that develops, manufactures and sells implantable phakic intraocular lenses — most notably the Visian/EVO line of implantable collamer lenses — used by ophthalmic surgeons to correct refractive errors such as myopia and astigmatism. The company markets its proprietary Collamer lens material and related surgical instruments to clinics and distributors around the world, relying on regulatory approvals and clinical data to support adoption in key markets. As a publicly traded company, STAAR generates revenue primarily from lens sales and aftermarket services and continues to invest in product development and surgeon training to expand the clinical applications and geographic reach of its vision-correction technologies.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue and China Impact

Q4 net sales: $57.8M (+18.1% y/y). Excluding China, Q4 net sales were $40.3M (down 2.1% y/y), indicating the China shipment/timing drove much of the quarter’s reported growth.

Margins and Drivers

Q4 gross margin improved to 75.7% from 64.7% a year ago; management attributed the increase to timing of cost recognition for a December 2024 China shipment, reduced period costs from cost reductions, and Swiss manufacturing ramp, partially offset by higher inventory provisions. Fiscal 2025 gross margin was 76.2% (vs. 76.3% in FY2024).

Profitability Metrics

Q4 net loss was $18.3M (‑$0.37 per share) versus a net loss of $34.2M a year ago. Adjusted EBITDA for Q4 was reported at breakeven (≈$(0.00) per share) compared with an Adjusted EBITDA loss of $20.8M in Q4 2024.

Full-Year 2025 Results

FY2025 net sales: $239.4M, down 23.7% y/y. Excluding China, FY2025 net sales were $161.7M, up 6.6% y/y. FY2025 net loss was $80.4M (‑$1.62 per share) and Adjusted EBITDA loss was $6.6M (‑$0.13 per share).

Balance Sheet and Cash

Cash, cash equivalents and investments available-for-sale totaled approximately $187.5M at year end. The company repurchased about 376,000 shares during FY2025.

Leadership and Corporate Actions

On Feb 2, 2026, STAAR appointed Warren Foust and Deborah Andrews as interim co‑CEOs and engaged Egon Zehnder to search for a permanent CEO. The company noted board and leadership transitions intended to support strategy execution and shareholder value creation.

Other Items

STAAR reiterated confidence in a clear path toward sustainable profitability and growth, cited a large addressable market for its EVO ICL technology and proprietary Collamer material, and hosted an earnings webcast on March 3, 2026 to discuss results and outlook.

Summarized from source with an LLMView Source

Key figures

44.6%1Y

-59.2%3Y

-78.0%5Y

Performance

64.1%1Y

61.0%3Y

61.9%5Y

Volatility